We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+23.43%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$16.4B
AUM Growth
-$5.58B
(-25%)
Cap. Flow
-$3.87B
Cap. Flow
% of AUM
-23.65%
Top 10 Holdings %
Top 10 Hldgs %
18.07%
Holding
3,458
New
283
Increased
974
Reduced
1,077
Closed
907
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$97.1M |
| 2 |
iShares Core S&P Small-Cap ETF
IJR
|
+$76.6M |
| 3 |
Lowe's Companies
LOW
|
+$75.4M |
| 4 |
Monster Beverage
MNST
|
+$64.6M |
| 5 |
FISV
Fiserv Inc
FISV
|
+$63.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Accenture
ACN
|
+$114M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$109M |
| 3 |
Trane Technologies
TT
|
+$106M |
| 4 |
Microsoft
MSFT
|
+$104M |
| 5 |
Mastercard
MA
|
+$104M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.03% |
| 2 | Healthcare | 13.89% |
| 3 | Financials | 11.27% |
| 4 | Consumer Discretionary | 8.92% |
| 5 | Industrials | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GWPH
1401
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $36K | ﹤0.01% |
300
| – | – |
|
|
AIMT
1402
DELISTED
Aimmune Therapeutics
AIMT
| $36K | ﹤0.01% |
2,195
-142
| -6% | -$2.41K |
|
|
IBTX
1403
DELISTED
Independent Bank Group, Inc.
IBTX
| $36K | ﹤0.01% |
915
-63
| -6% | -$2.04K |
|
1404
Cognex
CGNX
$9.62B
| $35K | ﹤0.01% |
600
| – | – |
|
|
VISN
1405
Vistance Networks Inc
VISN
$2.61B
| $35K | ﹤0.01% |
4,263
+204
| +5% | +$2.02K |
|
|
DEA
1406
Easterly Government Properties
DEA
$1.16B
| $35K | ﹤0.01% |
608
+432
| +245% | +$27.4K |
|
1407
iShares Global Clean Energy ETF
ICLN
$2.22B
| $35K | ﹤0.01% |
+2,800
| New | +$31.5K |
|
1408
IPG Photonics
IPGP
$3.4B
| $35K | ﹤0.01% |
219
-315
| -59% | -$44.9K |
|
1409
Oramed Pharmaceuticals
ORMP
$162M
| $35K | ﹤0.01% |
10,000
| – | – |
|
1410
Sabesp
SBS
$18.4B
| $35K | ﹤0.01% |
17,506
+154
| +0.9% | +$258 |
|
|
VSTO
1411
DELISTED
Vista Outdoor Inc.
VSTO
| $35K | ﹤0.01% |
2,533
+235
| +10% | +$2.35K |
|
1412
CVB Financial
CVBF
$4.02B
| $34K | ﹤0.01% |
1,830
+457
| +33% | +$8.72K |
|
1413
The Ensign Group
ENSG
$10.6B
| $34K | ﹤0.01% |
832
+358
| +76% | +$14.2K |
|
1414
Integer Holdings
ITGR
$3.39B
| $34K | ﹤0.01% |
467
+153
| +49% | +$11.1K |
|
1415
Nektar Therapeutics
NKTR
$2.39B
| $34K | ﹤0.01% |
98
-78
| -44% | -$24.3K |
|
1416
Invesco Large Cap Value ETF
PWV
$1.68B
| $34K | ﹤0.01% |
1,043
| – | – |
|
|
EGOV
1417
DELISTED
NIC Inc
EGOV
| $34K | ﹤0.01% |
1,509
-151
| -9% | -$3.57K |
|
1418
CareTrust REIT
CTRE
$10B
| $33K | ﹤0.01% |
2,015
+311
| +18% | +$5.43K |
|
1419
GDS Holdings
GDS
$5.93B
| $33K | ﹤0.01% |
415
-4,829
| -92% | -$299K |
|
1420
The Mosaic Company
MOS
$7.19B
| $33K | ﹤0.01% |
2,724
+675
| +33% | +$8.09K |
|
1421
PVH
PVH
$4.07B
| $33K | ﹤0.01% |
724
+383
| +112% | +$17.9K |
|
1422
SPX Corp
SPXC
$9.39B
| $33K | ﹤0.01% |
810
+366
| +82% | +$13.8K |
|
1423
Akebia Therapeutics
AKBA
$338M
| $32K | ﹤0.01% |
2,385
-2,121
| -47% | -$21.9K |
|
1424
Bread Financial
BFH
$4.32B
| $32K | ﹤0.01% |
890
+321
| +56% | +$11.4K |
|
1425
Horace Mann Educators
HMN
$2.11B
| $32K | ﹤0.01% |
904
+256
| +40% | +$9K |
|
Similar funds
EWA
MIC
P
OSAM
CB
EIM
SC
Glenmede Trust's Q2 2020 Portfolio in Review
As of Q2 2020, Glenmede Trust held 3,458 positions worth $16.4B, down 25% from $21.9B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Glenmede Trust withdrew a net $3.87B in Q2 2020, closing 907 positions and reducing 1,077 holdings. Its most notable exit was Raytheon Company, an estimated $66.5M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 19% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Glenmede Trust opened a new position in Carrier Global worth $21.3M.
- Glenmede Trust's largest Q2 2020 buy was Carrier Global: 960,042 shares worth $21.3M.
- Glenmede Trust added most to State Street SPDR S&P 500 ETF Trust in Q2 2020, an estimated $97.1M increase.
- Glenmede Trust's biggest Q2 2020 reduction was Accenture, cutting an estimated $114M.
- Glenmede Trust fully exited Raytheon Company in Q2 2020, selling an estimated $66.5M.
- Glenmede Trust's ten largest holdings make up 18% of its $16.4B portfolio in Q2 2020.
- Glenmede Trust opened 283 new positions and closed 907 in Q2 2020.
- Glenmede Trust's portfolio value fell 25% quarter-over-quarter to $16.4B.
Based on Glenmede Trust's 13F filing for Q2 2020, filed 14 Aug 2020.